Medicenna gains precedent-setting FDA approval to design a hybrid Synthetic Control Arm® for a Phase 3 registrational trial

Medicenna, developing MDNA55 for recurrent glioblastoma, faced difficulty recruiting and retaining patients for a traditional randomized Phase 3 trial in this aggressive cancer. Medidata AI built a Synthetic Control Arm from Phase 2 data to design a hybrid Phase 3 control combining historical patients with prospective controls, reducing the needed control group by roughly 100 patients. The page states the FDA granted precedent-setting approval for this design, improving enrollment odds for patients while preserving scientific rigor and accelerating trial timelines without compromising interpretability of results.

Medidata is a Dassault Systèmes company supplying the clinical-trial EDC and data platform (Rave) most sponsors and CROs already run live trials on, now with an AI layer built in.

This sits in the Ship stage of the AI use-case lifecycle: Named examples from the vendors pharma teams use to get an AI system live inside a real, regulated production workflow — validation, CRM, safety and clinical systems of record.